Search Results

You are looking at 1 - 5 of 5 items for

  • Author or Editor: P. Lees x
  • Refine by Access: All Content x
Clear All Modify Search


Objective—To investigate effects of the anti-arthritic agents hyaluronan and polysulfated glycosaminoglycan (PSGAG) on inflammatory metabolism in cultured equine synoviocytes.

Sample Population—Synoviocytes cultured from samples obtained from the metacarpophalangeal joints of 4 horses.

Procedure—Equine synoviocytes were grown in monolayer culture. Synoviocytes were stimulated with lipopolysaccharide (LPS) and simultaneously treated with various concentrations of hyaluronan or PSGAG for 48 hours. Three hyaluronan preparations were compared. Prostaglandin E2 (PGE2) concentrations in culture medium were measured, using radioimmunoassay.

Results—The highest concentrations of hyaluronan and PSGAG tested inhibited PGE2 production.

Conclusions and Clinical Relevance—Clinically achievable concentrations of hyaluronan and PSGAG inhibited PGE2 synthesis by cultured equine synoviocytes. This anti-inflammatory action may be a mechanism through which these agents exert anti-arthritic effects. The effect was obtained at concentrations that can be achieved by use of intra-articular, but not systemic, administration of hyaluronan or PSGAG. ( Am J Vet Res 2000;61:499–505)

Full access
in American Journal of Veterinary Research


Pharmacokinetic and pharmacodynamic variables of flunixin were studied in calves after IV administration of the drug at a dose rate of 2.2 mg/kg of body weight. The anti-inflammatory properties of flunixin were investigated, using a model of acute inflammation; this involved surgically implanting tissue cages at subcutaneous sites and stimulating the tissue cage granulation tissue by intracavitary injection of carrageenan. The actions of flunixin on exudate concentrations of several substances related to the inflammatory process, including proteases (metalloprotease [active and total] and cysteine and serine proteases), enzymes (lactate dehydrogenase, acid phosphatase, and β-glucuronidase [β-glu]), eicosanoid (prostaglandin E2 [pge 2], leukotriene B4, and serum thromboxane B2 [txb 2]) concentrations, and bradykinin (BK)-induced edema, were investigated.

Flunixin had a long elimination half-life—6.87 ± 0.49 hours—and volume of distribution was 2.11 ± 0.37 L/kg, indicating extensive distribution of the drug in the body. Body clearance was 0.20 ± 0.03 L/ kg/h.

Flunixin exerted inhibitory effects on serum txb 2 and exudate pge 2 concentrations, β-glu activity, and BK-induced swelling. Other enzymes and inflammatory mediators were not significantly affected. Pharmacokinetic/pharmacodynamic modeling of the data revealed similar mean concentration producing 50% of the maximal effect values for inhibition of exudate pge 2 and p-glu and of BK-induced swelling (0.070 ± 0.006, 0.064 ± 0.040, and 0.061 ± 0.030 μg/ml, respectively). A lower concentration producing 50% of the maximal effect value was obtained for inhibition of serum txb 2 concentration (0.023 ± 0.004 μg/ml). Differences also were observed in equilibration halflife for these actions, suggesting the existence of 3 distribution compartments correlating with 3 sites of action—a central compartment and shallow and deep peripheral compartments. Pharmacokinetic/pharma- codynamic modeling proved to be a useful analytical method, providing a quantitative description of in vivo drug pharmacodynamics and indicating possible mechanisms of action.

Free access
in American Journal of Veterinary Research


Objective—To establish pharmacokinetic and pharmacodynamic properties of a racemic mixture and individual R(–) and S(+) enantiomeric forms of ketoprofen (KTP) in sheep and determine pharmacodynamic variables of KTP by pharmacokinetic-pharmacodynamic modeling.

Animals—8 female Dorset crossbred sheep.

Procedure—A tissue cage model of inflammation was used. Carrageenan was administered into tissue cages. Time course of cyclooxygenase (COX)-2 inhibition was determined in vivo by measurement of exudate prostaglandin E2 (PGE2) concentrations. Time course of COX-1 inhibition was determined ex vivo by measurement of serum thromboxane B2 (TXB2) concentrations. In addition, plasma concentration-time course and penetration of KTP enantiomers into inflammatory exudate and transudate (noninflamed tissue cage fluid) were investigated. Four treatments were compared: placebo, racemic mixture (rac-KTP [3 mg/kg of body weight, IV]), S(+) KTP (1.5 mg/kg, IV),and R(–) KTP (1.5 mg/kg, IV).

Results—Both KTP enantiomers had elimination halflife and mean residence time measurements that were short and volume of the central compartment and steady state volume of distribution that were low. Clearance was rapid, particularly for R(–) KTP. Elimination of both enantiomers from exudate was > 10 times slower than from plasma. Both rac-KTP and the individual enantiomers significantly inhibited serum TXB2 concentrations for 12 hours. Rac-KTP and S(+) KTP, but not R(–) KTP, also significantly inhibited PGE2 synthesis in exudate for 12 hours.

Conclusions and Clinical Relevance—Inhibition of serum TXB2 concentration and exudate PGE2 synthesis for similar time courses after S(+) KTP administration indicates that it is a nonselective inhibitor of COX in sheep. ( Am J Vet Res 2001;62:77–86)

Full access
in American Journal of Veterinary Research
in Journal of the American Veterinary Medical Association


Objective—To establish pharmacokinetics of robenacoxib after administration to cats via the IV, SC, and oral routes.

Animals—24 cats.

Procedures—In a crossover design, robenacoxib was administered IV, SC, and orally (experiment 1) and orally (experiment 2) to cats with different feeding regimens. Blood robenacoxib concentrations were assayed, with a lower limit of quantification of 3 ng/mL.

Results—In experiment 1, geometric mean pharmacokinetic values after IV administration of robenacoxib were as follows: blood clearance, 0.44 L/kg/h; plasma clearance, 0.29 L/kg/h; elimination half-life, 1.49 hours; and volume of distribution at steady state (determined from estimated plasma concentrations), 0.13 L/kg. Mean bioavailability was 69% and median time to maximum concentration (Cmax) was 1 hour for cats after SC administration of robenacoxib, whereas mean bioavailability was 49% and 10% and median time to Cmax was 1 hour and 30 minutes after oral administration to cats after food withholding and after cats were fed their entire ration, respectively. In experiment 2, geometric mean Cmax was 1,159, 1,201, and 692 ng/mL and area under the curve from 0 to infinity was 1,337, 1,383, and 1,069 ng × h/mL following oral administration to cats after food withholding, cats fed one-third of the daily ration, and cats fed the entire daily ration, respectively.

Conclusions and Clinical Relevance—For treatment of acute conditions in cats, it is recommended to administer robenacoxib by IV or SC injection, orally after food withholding, or orally with a small amount of food to obtain optimal bioavailability and Cmax.

Full access
in American Journal of Veterinary Research